Physician profile
Amanda Barnes
NPI 1518480698
$3,041.07
in general payments reported to CMS, 2019-2025
29 companies · $672 in 2025
The $672 reported for 2025 was more than what 86% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $86.54 · 2021: $771 · 2022: $435 · 2023: $494 · 2024: $582 · 2025: $672.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,735 · Education: $13.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,734.90 |
| Education | $13.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $682.02 | 2020-2024 | Lo Loestrin Fe, Orilissa |
| Astellas Pharma US INC | $266.34 | 2023-2025 | Veozah |
| Mayne Pharma Commercial LLC | $217.01 | 2021-2025 | |
| Pfizer INC. | $166.08 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $151.63 | 2021-2025 | |
| Exeltis, USA INC. | $139.12 | 2023-2025 | Slynd |
| Sumitomo Pharma America, INC. | $133.39 | 2023-2025 | Myfembree |
| Millicent US INC | $121.80 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Merck Sharp & Dohme LLC | $117.63 | 2021-2025 | Gardasil 9 |
| Evofem Biosciences, INC. | $113.00 | 2021-2025 | Solosec, Phexx, Phexxi |
| Glaxosmithkline, LLC. | $107.27 | 2023-2024 | Trelegy Ellipta |
| Hologic Sales and Service, LLC | $99.19 | 2020-2024 | Acessa Provu System |
| Myovant Sciences INC. | $93.00 | 2021-2022 | |
| Sage Therapeutics, LLC | $92.11 | 2025 | Zurzuvae |
| Coopersurgical, INC. | $74.99 | 2021-2024 | Advincula Delineator Uterine Manipulator |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $70.31 | 2020-2021 | |
| Vertex Pharmaceuticals Incorporated | $66.91 | 2024-2025 | |
| Exact Sciences Corporation | $45.49 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Shield Therapeutics INC | $45.28 | 2022-2024 | |
| Organon LLC | $34.68 | 2021-2022 | |
| Aspira Women'S Health INC | $30.19 | 2022 | |
| Ascend Therapeutics US, LLC | $28.67 | 2023 | |
| Becton, Dickinson and Company | $25.56 | 2024 | Bd Onclarity |
| Supernus Pharmaceuticals, INC. | $25.40 | 2025 | Qelbree |
| Baxter Healthcare | $24.02 | 2022 | |
| Mylan Pharmaceuticals INC. | $20.45 | 2021 | |
| Agile Therapeutics, INC. | $20.01 | 2021 | |
| Ethicon US, LLC | $16.31 | 2023 | Enseal |
| Avion Pharmaceuticals | $13.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Barnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.